vs

Side-by-side financial comparison of INVESTORS TITLE CO (ITIC) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $69.5M, roughly 1.2× INVESTORS TITLE CO). On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs -1.6%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs 14.0%).

The Real Estate Title Insurance Company of Philadelphia was the world's first title insurance company.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

ITIC vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.2× larger
PRCT
$83.1M
$69.5M
ITIC
Growing faster (revenue YoY)
PRCT
PRCT
+21.8% gap
PRCT
20.2%
-1.6%
ITIC
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
14.0%
ITIC

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ITIC
ITIC
PRCT
PRCT
Revenue
$69.5M
$83.1M
Net Profit
$-31.6M
Gross Margin
64.9%
Operating Margin
13.8%
-4.1%
Net Margin
-38.1%
Revenue YoY
-1.6%
20.2%
Net Profit YoY
-27.9%
EPS (diluted)
$3.97
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ITIC
ITIC
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$69.5M
$76.4M
Q3 25
$73.0M
$83.3M
Q2 25
$73.6M
$79.2M
Q1 25
$56.6M
$69.2M
Q4 24
$70.6M
$68.2M
Q3 24
$68.8M
$58.4M
Q2 24
$65.4M
$53.4M
Net Profit
ITIC
ITIC
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$-29.8M
Q3 25
$12.2M
$-21.4M
Q2 25
$12.3M
$-19.6M
Q1 25
$3.2M
$-24.7M
Q4 24
$-18.9M
Q3 24
$9.3M
$-21.0M
Q2 24
$8.9M
$-25.6M
Gross Margin
ITIC
ITIC
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
ITIC
ITIC
PRCT
PRCT
Q1 26
-4.1%
Q4 25
13.8%
-40.6%
Q3 25
20.7%
-27.8%
Q2 25
21.5%
-28.0%
Q1 25
7.2%
-39.7%
Q4 24
15.3%
-28.9%
Q3 24
16.8%
-38.4%
Q2 24
17.2%
-50.3%
Net Margin
ITIC
ITIC
PRCT
PRCT
Q1 26
-38.1%
Q4 25
-39.1%
Q3 25
16.7%
-25.7%
Q2 25
16.7%
-24.7%
Q1 25
5.6%
-35.8%
Q4 24
-27.6%
Q3 24
13.5%
-35.9%
Q2 24
13.6%
-48.0%
EPS (diluted)
ITIC
ITIC
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$3.97
$-0.54
Q3 25
$6.45
$-0.38
Q2 25
$6.48
$-0.35
Q1 25
$1.67
$-0.45
Q4 24
$4.41
$-0.34
Q3 24
$4.92
$-0.40
Q2 24
$4.70
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ITIC
ITIC
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$89.6M
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$268.3M
$347.7M
Total Assets
$363.1M
$487.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ITIC
ITIC
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$89.6M
$286.5M
Q3 25
$110.8M
$294.3M
Q2 25
$90.1M
$302.7M
Q1 25
$81.7M
$316.2M
Q4 24
$83.8M
$333.7M
Q3 24
$112.9M
$196.8M
Q2 24
$111.2M
$214.1M
Total Debt
ITIC
ITIC
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
ITIC
ITIC
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$268.3M
$365.9M
Q3 25
$278.0M
$380.3M
Q2 25
$266.2M
$385.8M
Q1 25
$254.4M
$389.2M
Q4 24
$251.8M
$402.2M
Q3 24
$271.3M
$241.2M
Q2 24
$261.8M
$251.8M
Total Assets
ITIC
ITIC
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$363.1M
$508.1M
Q3 25
$363.3M
$511.5M
Q2 25
$345.8M
$513.1M
Q1 25
$333.8M
$519.4M
Q4 24
$333.6M
$534.0M
Q3 24
$352.0M
$374.1M
Q2 24
$340.3M
$374.4M
Debt / Equity
ITIC
ITIC
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ITIC
ITIC
PRCT
PRCT
Operating Cash FlowLast quarter
$30.9M
Free Cash FlowOCF − Capex
$25.4M
FCF MarginFCF / Revenue
36.5%
Capex IntensityCapex / Revenue
8.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$47.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ITIC
ITIC
PRCT
PRCT
Q1 26
Q4 25
$30.9M
$-10.3M
Q3 25
$17.2M
$-6.6M
Q2 25
$8.9M
$-15.0M
Q1 25
$-75.0K
$-17.0M
Q4 24
$29.8M
$-32.4M
Q3 24
$7.8M
$-18.8M
Q2 24
$8.4M
$-15.7M
Free Cash Flow
ITIC
ITIC
PRCT
PRCT
Q1 26
Q4 25
$25.4M
$-12.2M
Q3 25
$15.8M
$-9.5M
Q2 25
$7.3M
$-17.8M
Q1 25
$-1.4M
$-18.8M
Q4 24
$22.4M
$-33.6M
Q3 24
$6.1M
$-19.0M
Q2 24
$6.3M
$-16.8M
FCF Margin
ITIC
ITIC
PRCT
PRCT
Q1 26
Q4 25
36.5%
-15.9%
Q3 25
21.7%
-11.4%
Q2 25
9.9%
-22.5%
Q1 25
-2.5%
-27.2%
Q4 24
31.7%
-49.2%
Q3 24
8.8%
-32.6%
Q2 24
9.7%
-31.4%
Capex Intensity
ITIC
ITIC
PRCT
PRCT
Q1 26
Q4 25
8.0%
2.4%
Q3 25
1.8%
3.4%
Q2 25
2.1%
3.5%
Q1 25
2.4%
2.7%
Q4 24
10.5%
1.7%
Q3 24
2.5%
0.4%
Q2 24
3.2%
2.0%
Cash Conversion
ITIC
ITIC
PRCT
PRCT
Q1 26
Q4 25
Q3 25
1.40×
Q2 25
0.72×
Q1 25
-0.02×
Q4 24
Q3 24
0.84×
Q2 24
0.95×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ITIC
ITIC

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons